Summanr Low-density lipoprotein (LDL) uptake in gliomas was studied to find out if LDL has potential as a drug camrer of boron. especially for boron neutron capture therapy. Single photon emission tomography (SPET) was performed 2 h and 20 h after intravenous injection of autologous 9"9Tc-labelled LDL in four patients with untreated and five patients with recurrent glioma. 9'Tc-LDL uptake was compared with the uptake of 9'Tc-labelled human serum albumin (HSA). an established blood pool marker. The intra-and peritumoral distributions of radioactivity in the SPET images were not identical for radiolabelled LDL and HSA. The mean LDL tumour to brain ratio, determined from transversal SPET slices at 20 h post injection. was 1.5 in untreated and 2.2 in recurrent gliomas; the corresponding ratios for HSA were 1.6 and 3.4. The brain to blood ratio remained constant at 2 h and 20 h in both types of tumours. These data are not consistent with highly selective, homogeneous uptake of LDL in gliomas. However, the different tumoral distribution and rate of uptake of 9Tc-LDL, as compared with 9'Tc-HSA, indicate that the uptake of LDL is different from that of HSA and that further studies on the mechanism of LDL uptake in glioma are warranted.
the ten most common human tumours (Fogeiholm et al., 1984; Cancer Society of Finland, 1992) . More than half of the gliomas are malignant with a median survival time of about I year (Kalijo et al., 1991) . In recent decades there has been no significant improvement in survival of patients with malignant glioma in spite of efforts to improve conventional treatments and to develop new ones. Boron neutron capture therapy (BNCT) is a relatively new binary therapy utilising low-energy neutrons and the neutron capture reaction of boron (Barth and Soloway, 1992) . Gliomas have been treated with BNCI and are still the main target of research in this field (Barth and Soloway, 1992) . BNCT requires sufficiently high and selective uptake of boron in the tumour tissue. The boronated agent mainly used in BNCT has been watersoluble borocaptate (BSH). The tumour to brain (T:Br) boron concentration ratios obtained with BSH have been rather low and are apparently dependent on blood flow (Dewit et al., 1990 ; Barth and Soloway, 1992; Haritz et al., 1994) . Low-density lipoprotein (LDL), the main cholesterol carrier in blood, has been suggested as a more selective vehicle for boron since growing tumour tissue requires cholesterol for cell membrane synthesis (Kahl and Callaway,. 1989; Laster et al., 1991; Vitols, 1991) .
LDL is carried into the cell by a receptor-mediated mechanism (Brown and Goldstein, 1986) . Leukaemic cells, lung cancers, brain tumours and glioma cell lines have LDL receptors (Murakami et al., 1990; Rudling et al., 1990; Vitols et al., 1990 Vitols et al., , 1992 and LDL has been used for drug delivery in ovarian cancer therapy trials (Gal et al., 1981; Filipowska et al., 1992) . LDL can be boronated by substituting carborane esters of fatty alcohols for core cholesterol esters (Kahl and Callaway, 1989) . The amount of LDL taken up by gliomas in vivo is not known. High-grade gliomas exhibit vast morphological, biochemical, immunochemical, biological and chromosomal heterogeneity (McComb and Bigner, 1984 
Results
In the SPET images 9Tc-LDL and 99mTc-HSA accumulated in the tumour area as defined by the CT scan (Figures 1-4) . The distribution of radioactivity in the tumour areas was not identical for 'Tc-LDL and 991Tc-HSA, and particularly at 20 h dissimilarities were observed, as can be seen in the three studies presented in Figures 1-3 . The tumour to brain (T:Br) ratio increased from 2 h to 20 h (Figure 4 ) in all patients (Table II) (0.09-2.29 x 10-3% ID g-') the mean being 0.27 mCi g-' (1.05 x 10-3% ID g-'). There was no correlation between the T:B ratios derived from the SPET images or the T:B ratio determined from the tumour samples. Lees et al., 1985; Goldstein and Brown. 1989; Lees and Lees, 1991; Virgolini et al., 1991; Leitha et al., 1993 In conclusion, this study shows that the magnitude of 9'Tc-LDL accumulation in human malignant glioma is c rTc-LDL ua x ooma J Leppai et al 387 similar to that of 'Tc-HSA and that the mechanism of LDL uptake may be mostly passive diffusion, in addition to a blood pool effect. However, the different intratumoral distribution of radioactivity in patients given LDL and albumin, along with the different rate of uptake in the tumours, shows that the behaviour of these two substances in gliomas is not identical. Consequently, the uptake of LDL might therefore result from both non-specific and LDL receptor-mediated processes. Further studies on cellular and receptor mechanisms will be needed to elucidate the nature of LDL uptake into human gliomas.
